A study that uses MT-II for a pigmentation endpoint may need to account for central, autonomic, appetite, sexual-function, or behavioural confounders depending on model and exposure
+25
Retatrutides nausea rate of 28% is substantially lower than Wegovys 44%, despite delivering nearly 10 percentage points more weight loss
Individual results vary based on your health, the plan prescribed, and many factors outside any single treatment, and no specific outcome is guaranteed
What the Evidence Does NOT Show Because the marketing around KLOW is so confident, it is worth stating plainly and in one place what the current evidence does not establish
[DOI] [PMC free article] [PubMed] [Google Scholar] Yamamoto K., Miyoshi-Koshio T., Utsuki Y., Mizuno S., Suzuki K